

SRXH makes a bold investment
I wanted to do a write-up on a company SRXH had just recently invested in called Greenland Mines Ltd (GRML)
From what I can tell, the company maintains a biotech pipeline targeting neurodegenerative diseases, specifically candidate KLTO-202 for Amyotrophic Lateral Sclerosis (ALS) and KLTO-101 for Alzheimer's disease, while simultaneously managing its flagship mining asset, the Skaergaard Project located in Southeast Greenland. Though geological reports estimate the Skaergaard deposit holds substantial potential mineral resources, including roughly 25.4 million ounces of Palladium Equivalent and 23.5 million ounces of Gold Equivalent, Greenland Mines Ltd operates with $0.00 in current revenue and faces severe capital-intensive extraction challenges due to the remote Arctic climate and a total lack of regional infrastructure.
To fund its operations and upcoming 2026 diamond drilling programs, Greenland Mines has aggressively sought external financing, raising $3.75 million through a private stock placement in mid-June 2026 before capturing the attention of institutional platforms.
On July 2, 2026, SRX Global, Inc. (NYSE American: SRXH), announced an investment into Greenland Mines Ltd. SRX Global deployed its capital to gain direct multi-asset exposure to the North Atlantic Critical Metals Corridor, betting on GRML’s potential to produce rare earth magnet materials and precious metals vital to technology and industrial manufacturing sectors.
This partnership directly links the financial trajectory of SRX Global and its shareholders to the high-risk, highly speculative exploration outcomes of a micro-cap hybrid entity carrying a market capitalization of approximately $35 million.
After my researching of the investment SRXH recently made, I personally see this as a better than I first expected investment. The chosen sector from a market shift standpoint is exactly where the market is shifting towards. We will see.